{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T16:25:55Z","timestamp":1772036755522,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd007204","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2009,4,15]],"date-time":"2009-04-15T00:00:00Z","timestamp":1239753600000}}],"reference-count":37,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007204.pub2","type":"journal-article","created":{"date-parts":[[2009,4,15]],"date-time":"2009-04-15T15:10:56Z","timestamp":1239808256000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Cannabinoids for the treatment of dementia"],"prefix":"10.1002","volume":"2010","author":[{"given":"Sarada","family":"Krishnan","sequence":"first","affiliation":[{"name":"Maudsley Hospital; Mental Health of Older Adults; Denmark Hill London UK SE5 8AZ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"Cairns","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry; Department of Psychological Medicine; Weston Education Centre 10 Cutcombe Road London UK SE5 9RJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Howard","sequence":"additional","affiliation":[{"name":"Institute of Psychiatry; London UK SE5 8AF"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,15]]},"reference":[{"key":"10.1002\/14651858.CD007204.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/(SICI)1099-1166(199709)12:9<913::AID-GPS663>3.0.CO;2-D","article-title":"Effects of dronabinol on anorexia and disturbed behaviour in patients with Alzheimer's Disease.","volume":"12","author":"Volicer","year":"1997","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s00213-006-0343-1","article-title":"Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia.","volume":"185","author":"Walther","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0003|cit3","unstructured":"Walther S Placebo-controlled, randomised, double blind crossover trial on dronabinol, a cannabinoid-1-receptor agonist, for behavioral and circadian rhythm disturbances in dementia Registration-number 2007DR2217 (Swissmedic trial registry)"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0004|cit4","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1474-4422(03)00381-8","article-title":"The therapeutic potential of cannabis","volume":"2","author":"Baker","year":"2003","journal-title":"The Lancet Neurology"},{"issue":"1","key":"10.1002\/14651858.CD007204.pub2-BIB0006|cit6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003476.pub2","article-title":"Atypical antipsychotics for aggression and psychosis in Alzheimer's disease","author":"Ballard","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD007204.pub2-BIB0007|cit7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005593","article-title":"Cholinesterase inhibitors for Alzheimer's disease","author":"Birks","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/sj.bjp.0707446","article-title":"Alzheimer's disease; taking the edge off with cannabinoids?","volume":"152","author":"Campbell","year":"2007","journal-title":"British Journal of Pharmacology"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJM198312013092204","article-title":"Bias in treatment assignment in controlled clinical trials","volume":"309","author":"Chalmers","year":"1983","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"M77","DOI":"10.1093\/geronj\/44.3.M77","article-title":"A description of agitation in a nursing home","volume":"44","author":"Cohen-Mansfield","year":"1989","journal-title":"Journal of Gerontology"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1742-2094-2-29","article-title":"Stimulation of CB2 suppresses microglial activation","volume":"2","author":"Ehrhart","year":"2005","journal-title":"Journal of Neuroinflammation"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1021\/mp060066m","article-title":"A molecular link between the active component of marijuana and Alzheimer's disease pathology","volume":"3","author":"Eubanks","year":"2006","journal-title":"Molecular Pharmaceutics"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0013|cit13","unstructured":"Centre for Drug Evaluation and Research FDA public health advisory: deaths with antipsychotics in elderly patients with behavioural disturbances FDA April 2005"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0014|cit14","volume-title":"Marihuana, the forbidden medicine","author":"Grinspoon","year":"1993"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1517\/13543784.11.10.1365","article-title":"The therapeutic potential of the cannabinoids in neuroprotection","volume":"11","author":"Grundy","year":"2002","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"8268","DOI":"10.1073\/pnas.95.14.8268","article-title":"Cannabidiol and delta-9-tetrahydrocannabinol are neuroprotective antioxidants","volume":"95","author":"Hampson","year":"1998","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa066583","article-title":"Donepezil for the treatment of agitation in Alzheimer's disease","volume":"357","author":"Howard","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1124\/pr.54.2.161","article-title":"International Union of Pharmacology XXVII. Classification of cannabinoid receptors","volume":"54","author":"Howlett","year":"2002","journal-title":"Pharmacological Reviews"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0019|cit19","volume-title":"The science of marijuana","author":"Iversen","year":"2000"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"P3","DOI":"10.1093\/geronb\/51B.1.P3","article-title":"Observed affect in nursing home residents with Alzheimer's disease","volume":"51B","author":"Lawton","year":"1996","journal-title":"Journals of Gerontology. Series B, Psychological sciences and social sciences"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/gps.499","article-title":"Alzheimer's disease in the UK: comparative evidence on cost of illness and volume of health services research funding","volume":"16","author":"Lowin","year":"2001","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/346561a0","article-title":"Structure of a cannabinoid receptor and functional expression of the cloned cDNA","volume":"346","author":"Matsuda","year":"1990","journal-title":"Nature"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's Disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0024|cit24","unstructured":"Medicines and Healthcare Products Regulatory Agency New advice issued on risperidone and olanzepine MHRA March 2004"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1523\/JNEUROSCI.19-08-02987.1999","article-title":"Cannabinoids and neuroprotection in global and focal cerebral ischaemia and in neuronal cultures","volume":"19","author":"Nagayama","year":"1999","journal-title":"Journal of Neuroscience"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000100778","article-title":"Neuropsychological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain","volume":"54","author":"Onaivi","year":"2006","journal-title":"Neuropsychobiology"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0027|cit27","first-page":"333","article-title":"The impact of dementia on the family","volume":"248","author":"Rabins","year":"1982","journal-title":"Journal of the American Medical Society"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1523\/JNEUROSCI.4540-04.2005","article-title":"Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation","volume":"25","author":"Ramirez","year":"2005","journal-title":"The Journal of Neuroscience"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1001\/jama.294.15.1934","article-title":"Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials","volume":"294","author":"Schneider","year":"2005","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/01.JGP.0000200589.01396.6d","article-title":"Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized placebo-controlled trials","volume":"14","author":"Schneider","year":"2006","journal-title":"American Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1124\/mol.54.3.459","article-title":"Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity","volume":"54","author":"Shen","year":"1998","journal-title":"Molecular Pharmacology"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1176\/ajp.147.8.1049","article-title":"Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease","volume":"147","author":"Steele","year":"1990","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1126\/science.1115740","article-title":"Identification and functional characterization of brainstem cannabinoid CB2 receptors","volume":"310","author":"Sickle","year":"2005","journal-title":"Science"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/(SICI)1099-1166(199709)12:9<913::AID-GPS663>3.0.CO;2-D","article-title":"Effects of dronabinol on anorexia and disturbed behaviour in patients with Alzheimer's disease","volume":"12","author":"Volicer","year":"1997","journal-title":"International Journal of Geriatric Psychiatry"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s00213-006-0343-1","article-title":"Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia","volume":"185","author":"Walther","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD007204.pub2-BIB0037|cit37","volume-title":"The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research","author":"World Health Organisation","year":"1993"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD007204.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T09:31:26Z","timestamp":1759397486000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007204.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Dementia and Cognitive Improvement Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2009,4,15]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007204.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,15]]}}}